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Background: Co-morbid major depression is a significant problem among patients with type 2 diabetes mellitus
and/or coronary heart disease and this negatively impacts quality of life. Subthreshold depression is the most
important risk factor for the development of major depression. Given the highly significant association between
depression and adverse health outcomes and the limited capacity for depression treatment in primary care, there is
an urgent need for interventions that successfully prevent the transition from subthreshold depression into a major
depressive disorder. Nurse led stepped-care is a promising way to accomplish this. The aim of this study is to
evaluate the cost-effectiveness of a nurse-led indicated stepped-care program to prevent major depression among
patients with type 2 diabetes mellitus and/or coronary heart disease in primary care who also have subthreshold
depressive symptoms.
Methods/design: An economic evaluation will be conducted alongside a cluster-randomized controlled trial in
approximately thirty general practices in the Netherlands. Randomization takes place at the level of participating
practice nurses. We aim to include 236 participants who will either receive a nurse-led indicated stepped-care
program for depressive symptoms or care as usual. The stepped-care program consists of four sequential but
flexible treatment steps: 1) watchful waiting, 2) guided self-help treatment, 3) problem solving treatment and 4)
referral to the general practitioner. The primary clinical outcome measure is the cumulative incidence of major
depressive disorder as measured with the Mini International Neuropsychiatric Interview. Secondary outcomes
include severity of depressive symptoms, quality of life, anxiety and physical outcomes. Costs will be measured from
a societal perspective and include health care utilization, medication and lost productivity costs. Measurements will
be performed at baseline and 3, 6, 9 and 12 months.
Discussion: The intervention being investigated is expected to prevent new cases of depression among people
with type 2 diabetes mellitus and/or coronary heart disease and subthreshold depression, with subsequent
beneficial effects on quality of life, clinical outcomes and health care costs. When proven cost-effective, the
program provides a viable treatment option in the Dutch primary care system.
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Subthreshold depression, the presence of symptoms of
depression without fulfilling the criteria for major de-
pression, is the strongest predictor for the onset of major
depression [1,2]. Currently, major depression is a sub-
stantial health problem throughout the industrialised
world [3]. The 12 month prevalence of major depression
ranges between 3 and 9% in high-income countries [4,5].
Among patients with type 2 diabetes mellitus (DM2)
and/or coronary heart disease (CHD) estimates of the 12
month prevalence of major depression usually range
from 10% to 20% [6-8]. Even more patients with DM2
and/or CHD experience subthreshold depression, i.e.
25%-40% [9,10]. More than 40% of diabetic patients with
subthreshold depression will develop major depression
within two years [9]. Similar estimates are found for pa-
tients diagnosed with CHD [11].
Depression has been shown to adversely affect self-
care and medication adherence related to DM2 and
CHD [12,13], to negatively impact quality of life [14,15]
and to be associated with poor health outcomes and an
increased risk of mortality [16,17]. Moreover, DM2 and
CHD patients with depression use healthcare services
more often than their non-depressed counterparts,
which is associated with a substantial increase in health
care related costs. This effect cannot be explained by an
increase in mental health care costs alone and remains
present after adjusting for co-morbid medical conditions
[18-21]. In addition, depression is associated with in-
creased work absenteeism, which raises the total societal
costs of depression even more [22].
Unfortunately, even when optimal treatment is given
to all patients with major depression, only about 27 per-
cent of the total disease burden can be averted [23].
Therefore, prevention of the onset of major depression
among high risk patients may be a promising solution to
reduce the burden for both patients and society substan-
tially [24].
Meta analyses show that using preventive interven-
tions, a reduction of about 25% in the incidence of major
depression can be obtained [2,25]. Especially promising
are preventive interventions that are offered in a
stepped-care format [25]. The aim of stepped-care inter-
ventions is to maximize the effectiveness of an interven-
tion while making best use of available resources by
offering the least intensive treatment necessary and bytailoring the treatment to the patient’s preferences. By
using such a format, it is possible to reduce the relative
risk of the onset of depression by as much as 50%
[25-27].
There is also evidence that stepped-care interventions
can be used to treat existing major depression among
patients with DM2 in primary care [28]. This stepped-
care depression treatment was shown to be cost-
effective in comparison with usual care as well. The
additional costs associated with the implementation of
the stepped-care program did not result in higher total
health care costs over respectively a 2- and 5- year
period [29,30]. This effect remained after adjusting for
co-morbid medical conditions. A more recent study
showed that a stepped-care program is effective in im-
proving disease control in chronically ill patients with
existing major depression [31]. All these findings com-
bined suggest that stepped-care is a promising method
to not only treat major depression in patients with DM2
and/or CHD, but also to prevent the onset of this dis-
order in these patient groups. However, to the best of
our knowledge, there are no studies evaluating the cost-
effectiveness of a stepped-care program to prevent de-
pression among DM2 and CHD patients.
Therefore, this study aims to evaluate the cost-
effectiveness of a nurse-led indicated stepped-care pro-
gram to prevent depression among primary care patients
with type 2 diabetes mellitus and/or coronary heart dis-
ease and subthreshold depression in comparison with
usual care.Methods/design
Design
An economic evaluation from a societal perspective will
be performed alongside a multi-center, cluster random-
ized controlled trial with a one year follow up.Ethical approval
The study protocol was approved by the Ethics Commit-
tee of the VU University Medical Centre (NL39261.029.
12, registration number 2012/223) and will be conducted
according to the principles of the Declaration of Helsinki
(version 2008) and the Dutch Medical Research Involv-
ing Human Subjects Act (WMO).
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The study will be carried out in approximately thirty
general practices in the Netherlands. To select these
practices, we will make use of the Academic Network
of General Practitioners (GPs) of the Department of
General practice and of the VU medical centre.
Randomization
Randomization will be done at the level of the participat-
ing practice nurses to avoid contamination between the
treatment groups and will be performed by a statistician
blinded to characteristics of the general practices using a
computer generated list of random numbers. Before pa-
tients are recruited, participating practices will be ran-
domly allocated to serve as intervention practices where
the stepped-care treatment will be implemented, and
control practices where care as usual will be given. Pa-
tients will be allocated to either one of the treatment
conditions, based on the general practice where they are
registered. Blinding of patients, GPs and practice nurses
is not possible due to the nature of the intervention.
Participants
Patients are eligible for this study if they are 18 years or
older, are treated for DM2 and/or CHD in primary care,
and have subthreshold depressive symptoms (a score of
6 or more on the Patient Health Questionnaire-9, or
PHQ-9 [32]) without fulfilling the criteria for major de-
pression according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV), as measured
with the Mini International Neuropsychiatric Interview
(MINI) [33].
Patients are excluded from participation in the study
when they have a major depressive disorder; cognitive
impairment or dementia; a psychotic or terminal illness;
a history of (a) suicide attempt(s); or insufficient Dutch
language skills, visual impairments or illiteracy. Also, pa-
tients cannot participate when they are pregnant, taking
antidepressant medication, or when they have lost a sig-
nificant other in the past 6 months.
Recruitment
To recruit eligible patients, in all participating general
practices an initial list of adult patients with DM2 and/
or CHD is composed, based on diagnoses classified
using the ICPC (International Classification of Primary
Care) in the medical electronic information system; see
Additional file 1 for details. This list is given to the gen-
eral practitioner, who checks the preset inclusion criteria
and excludes all patients that fulfill our preset exclusion
criteria, based on the medical file and experiences with
the patient. All remaining eligible patients will receive a
letter on behalf of the general practitioner, in which all
(at that point) necessary information regarding thestudy, as well as an invitation to participate is included.
When patients consider to participate, they are asked to
fill out a two question screening form (Patient Health
Questonnaire-2, or PHQ-2 [34]) that will be provided
with the information letter and send it back using a
prestamped envelope. All patients with a PHQ-2 score
of 2 or more [34,35] will receive additional information
from the research team. Based on this information in-
formed consent is obtained for a telephone interview.
During this interview the Dutch version of the PHQ-9
[36] and the MINI [37] will be administered. Patients
scoring 6 points or more on the PHQ-9, but not having
a major depression according to the MINI are eligible
for the study and will be asked for written informed con-
sent to participate. From this point on, patients are
either enrolled in the stepped-care program or will re-
ceive care as usual, depending on the general practice at
which they are registered. An overview of the study
design and patient flow is provided in Figure 1.
Intervention
The intervention is modelled after the flexible stepped-
care intervention developed by van ‘t Veer-Tazelaar et al.
[26]. After receiving a specially developed training, prac-
tice nurses in the intervention practices will act as care
managers and work together with the General Practi-
tioner (GP) to provide the stepped-care treatment. The
care managers coordinate the execution of the stepped-
care program that consists of four evidence-based subse-
quent treatment steps, lasting 3 months each. The flow
of participants in the intervention group through the
stepped-care program depends on their depressive symp-
tom level, measured using the PHQ-9 every 3 months dur-
ing 1 year. Participants who still have elevated depressive
symptom levels (i.e. a PHQ-9 score of 6 or more) after
concluding a step, are offered participation in the next
step. A score below the cut off point results in a period of
watchful waiting until an elevated PHQ-9 score indicates
the need for the subsequent step of the intervention. By
only offering more intensive treatment to patients who
continue to have elevated depressive symptom scores, it is
expected that patients will receive treatment tailored to
their needs and that available resources are more effi-
ciently used by providing the more intensive treatments
only to those who need this. Patients who meet the MINI
diagnostic criteria for major depression at baseline or at 3,
6, 9 or 12 months are referred to their GP by the practice
nurse for further assessment. The following treatment
steps are offered to participants:
Step 1: Watchful waiting
The first 3 months consist of watchful waiting, because
depressive symptoms often disappear spontaneously over
time [26]. After inclusion and obtaining informed
Figure 1 Overview of the study design and patient flow.
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an introductory consultation. During this consultation
patients will get acquainted with the care manager and
they will receive an information brochure about mild de-
pression with simple advices on how to cope with mild
depressive symptoms. Patients will be informed about
the stepped-care program and its rationale. In this step,
no therapeutic intervention will take place.
Step 2: Guided self-help treatment
During this step, participants are offered a self-help
course that is specially designed for patients with a
chronic physical illness and depressive complaints [38].
During a visit to the general practice, the care manager
will give the patient all necessary materials and explain
the self-help course. Participants can work through thecourse at their convenience. In doing so, they will be
supported by their care manager, who will contact them
every other week by phone to monitor their progress. If
it is clear that after two weeks the patient has not started
the course yet, the care manager will use motivational
interviewing techniques by phone to activate the patient.
When this does not have the intended activating effect
on the patient after two more weeks, the care manager
invites the patient to come to the practice to discuss the
current depressive symptoms (a PHQ-9 will be adminis-
tered). When depressive symptoms still exist, patients
are offered to progress early to step 3.
Step 3: problem-solving treatment
In this step, participants are offered Problem Solving
Treatment (PST) by the care manager. PST is a brief
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tical skill building. It consists of a maximum of 7 ses-
sions during which the stages of problem solving are
explained and then applied to problems encountered in
daily life. The goal of PST is to help patients regain con-
trol of their lives [39,40].
Step 4: Referral to general practitioner
Participants with continuously elevated PHQ-9 scores
after 9 months will be referred to their general practi-
tioner by the care manager for further assessment of
their depressive symptoms. The GP receives a summary
of the treatment provided to discuss with their patient.
Usual care
In the usual care practices, practice nurses and GPs will be
blinded to which patients are participating in the study.
They will not receive any training and will provide care as
usual to all their patients according to existing clinical
guidelines [41-43]. Participants in the usual care group will
have unrestricted access to care as normally provided by
their general practitioner. Their healthcare uptake (includ-
ing use of prescribed medication) will be recorded.
Training of the practice nurses
In the intervention practices, the practice nurses who
are going to provide the stepped-care treatment will at-
tend a two day training. This training focuses on how to
implement the stepped-care program, how to provide
guidance with the self help course using motivational
interviewing techniques and how to provide the PST.
The motivational interviewing techniques and the PST
will be taught by a professional trainer. Before the trial
starts, the trained practice nurses will perform two prac-
tice sessions of PST by telephone. These sessions will be
audio taped and evaluated by the training staff to detect
possible competence and/or adherence issues. During
the trial, all practice nurses are regularly supervised by
the training staff. Nurses can also contact the training
staff to discuss any questions or problems, should they
arise. When practice nurses have previously received
training in motivational interviewing and/or PST, they
are offered to follow a personalized training program.
Outcomes
The primary clinical outcome is the cumulative inci-
dence of DSM-IV major depressive disorder after 12
months according to the Mini International Neuro-
psychiatric Interview (MINI) [33,37]. The MINI will be
administered by telephone at baseline and after 6 and 12
months after baseline by qualified research assistants.
Depression severity will be measured using the PHQ-9
[32,44]. The PHQ-9 is a widely used validated instrument
to measure depression symptoms in general practice.Quality of life will be measured using the EuroQol
(EQ-5D) [45]). The obtained EQ-5D scores will be
used to calculate utilities according to the Dutch tariff.
QALYs will be calculated using the area-under-the-curve
method with linear interpolation between time points.
For the economic evaluation, costs will be measured
using the TiC-P questionnaire [46]. Costs that will be in-
cluded are costs for healthcare utilization, informal care,
and work absenteeism and presenteeism. Medication use
will be retrieved from the patient’s pharmacy. If avail-
able, Dutch guideline prices will be used to value re-
source use. Medication use will be valued using prices of
the Royal Dutch Society for Pharmacy. Lost productivity
costs will be calculated according to the friction cost ap-
proach (friction period 154 days) using the mean age-
and sex-specific income of the Dutch population.
According to the friction cost approach a sick employee
is replaced after a certain amount of time (the friction
period) after which there are no lost productivity costs
anymore. All costs will be adjusted to the year in which
most data is collected using consumer price indices.
All secondary outcomes mentioned above will be ad-
ministered at baseline, 3, 6, 9 and 12 months after inclu-
sion through web-based questionnaires. If patients do
not have access to the internet or prefer hard copies, we
will provide these. In the intervention group, the PHQ-9
will also be administered by the nurse in the general
practice for clinical monitoring and adjusting treatment
when necessary.
Other secondary clinical outcomes include blood pres-
sure, low-density lipoprotein (LDL) cholesterol and
glycosylated haemoglobin (HbA1C). These outcomes
will be measured at baseline and at 12 months follow-up
and are performed as part of the usual care for this
group of patients. Therefore, patients do not undergo
any extra physical measurements.
To be able to control for possible confounders, demo-
graphics will be measured at baseline, along with per-
sonal and family history of mood disorders, using a
subset of the Diagnostic Interview Schedule (DIS) [47].
The occurrence of co-morbid chronic illnesses will be
assessed with the Dutch questionnaire chronic illnesses
[48] at baseline and after 6 and 12 months, as well as
locus of control [49]and social support [50]. All these
measurements were previously used for the same pur-
poses in the West Friesland Study [51]. In addition to
this, anxiety symptoms will be measured at baseline, 3,
6, 9 and 12 months by the Hospital Anxiety and Depres-
sion Scale- Anxiety (HADS-A) [52].
After 12 months the uptake of the stepped-care pro-
gram will be evaluated. The number of contacts with the
care manager, the number of PST sessions, antidepres-
sant use, and the number of referrals to the GP will be
assessed by the care manager in the intervention group.
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tice will be assessed using the TiC-P questionnaire [46].
A process evaluation will be performed in which the
barriers and facilitators of the stepped-care program and
the experiences with the program will be evaluated. This
will be done by organizing focus groups among volun-
teering patients, general practitioners and primary care
nurses. In addition, satisfaction with the received care
will be measured in all patients after 12 months by using
the CSQ [53,54]. An overview of all measurements and
instruments is provided in Table 1.Sample size
The trial is powered to detect a difference of 15% in the
cumulative incidence rates of MINI/DSM-IV depressive
disorder between the conditions after 1 year. The inci-
dence rate is expected to be 30% in the usual care group
and 15% in the intervention group based on findings
from earlier studies [2,25,26]. Using a standard sample
size calculation, 121 patients per group are needed, as-
suming a power of 0.8 and an alpha of 0.05. However,
we need to correct for the fact that there is a multilevel
setting with three levels: GPs, patients and measure-
ments. Therefore we have first adjusted for the fact that
we do not have one, but multiple measurements per pa-
tient. Assuming these measurements are clustered with
an intraclass correlation (ICC) of 0.45, seventy-one pa-
tients per group are needed. Subsequently, we adjusted
this figure further for clustering of patients within GP
practices. Assuming an ICC of 0.05 for clustering of pa-
tients within the 30 GP practices, we need a total of 177
patients. Finally, we adjusted for a dropout rate of 25%,
which means that 236 patients (118 patients per group)
need to be included in this trial. This power calculation
is based on the method described by Twisk in 2006 [55].Table 1 Overview of all measurements and instruments
screening baseline
Depression symptoms (PHQ-2) x
Demographics x
Depression symptoms (PHQ-9) x
Clinical depression (MINI) x
Health care costs (Tic-P) x
Quality of life (EQ-5D) x
Anxiety (HADS-A) x
Personal and family history (DIS) x
Social support x
Existing chronic illnesses x
Locus of control x
Satisfaction with provided care (CSQ)Statistical analyses
Baseline data will be presented comparing the two treat-
ment groups.
All analyses will be on an intention-to-treat basis. Differ-
ences between the stepped-care group and the usual care
group will be tested using mixed model analyses. To test
the cumulative incidence of depression over time, logistic
mixed model analysis will be used. The obtained odds ratio
describes the reduction in the risk of a MINI/DSM-IV de-
pressive disorder in the intervention group relative to the
control group. Linear and logistic mixed models
(depending on the outcome) will also be used to test differ-
ences in symptoms of depression and anxiety and quality
of life between both groups over time. If necessary, the
models will be adjusted for confounders.
Sub group analyses will be performed to check for an
interaction effect between depression severity at baseline
and improvement in depressive symptoms at 12 months.
In case of unequal distributions of demographic variables
between the two treatment groups, multivariate analyses
techniques will be used to correct for these differences.
Economic evaluation
Both a cost-effectiveness analysis and a cost-utility ana-
lysis will be performed. Missing cost and effect data will
be imputed using multiple imputation according to the
MICE algorithm developed by Van Buuren [56]. The
results of the imputed datasets will be pooled using
Rubin’s rules [57]. Costs typically have a highly skewed
distribution. Policy makers want to have information on
the difference in mean total costs between the two treat-
ment groups in order to be able to estimate the total
health care budget needed for a specific condition [58].
Therefore, bias-corrected and accelerated bootstrapping
with 5000 replications will be used to estimate 95% con-
fidence intervals around the mean difference in total3 months 6 months 9 months 12 months
x x x x
x x
x x x x
x x x x
x x x x
x x
x x
x x x x
x
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effectiveness ratios (ICERs) will be calculated by dividing
the difference in mean total costs between the treatment
groups, by the difference in mean effects between the
treatment groups. Bootstrapping will also be used to esti-
mate the uncertainty surrounding the ICERs, which will
be graphically presented on cost-effectiveness planes.
Cost- effectiveness acceptability curves will be estimated
as well. Cost-effectiveness acceptability curves show the
probability that the stepped-care program is cost-effective
in comparison with usual care for a range of different ceil-
ing ratios (i.e. the willingness to pay for 1 extra recovered
patient), thereby showing decision uncertainty [59].
Discussion
Based on earlier studies, there is substantial evidence
that stepped-care programs for depression among pri-
mary care patients are effective in both improving and
preventing depression. However, evidence concerning
the costs and effects of such programs among patients
with DM2 and/or CHD and subthreshold depression in
general practices is still missing.
Given the large number of DM2 and CHD patients
with depressive symptoms, and the limited capacity for
depression treatment in primary care, there is an urgent
need to improve care for these patients. Since the pres-
ence of subthreshold depressive symptoms is the largest
risk factor for developing major depression, targeting
preventive treatments to patients at risk for developing a
major depression is a viable option to reduce the burden
of depression in primary care. Stepped-care interventions
are a very promising method to achieve this goal. The key
of stepped-care, delivered by a care manager, is that treat-
ment is tailored to the needs and preferences of the pa-
tient while making the best use of available recourses.
This will help optimizing health related outcomes, as well
as keeping the treatment affordable by saving available re-
sources for patients who really need them.
By testing a stepped-care program to prevent depres-
sion among high risk DM2 and/or CHD patients in a
primary care setting, this study is highly clinically and
societally relevant. Moreover, because a structured
evaluation of the feasibility of the stepped-care program
is explicitly taken into account in the study design, the
results of this cluster randomised controlled trial will
greatly contribute to the practical evidence about pre-
ventive treatment options for depression in patients with
DM2 and/or CHD in general practice.
A strength of this study is that a pragmatic study design
is employed; meaning that patients, treatments and proce-
dures are similar to daily clinical practice. This greatly en-
hances the generalizability of the findings of the study and
therefore the possibilities to implement the Step-Dep
treatment in a real-life primary care setting.The relatively short 12 month follow-up period may
turn out to be a limitation of this trial. It is possible that
the potential health benefits of participating in the
stepped-care program will not yet be fully visible after
one year. Especially the beneficial effects of having less
depressive symptoms on health care utilisation, work ab-
senteeism, and clinical outcomes such as Hb1Ac, blood
pressure and LDL cholesterol, may take longer than the
follow up period of one year to reach full development.
Katon and his colleagues, for example, found a signifi-
cant reduction in total health care costs among DM2 pa-
tients that participated in a stepped-care intervention to
treat major depression after two years, but not yet after
12 months [30]. Other studies report similar results
[60-62]. These findings can be explained by the fact that
the extra costs of stepped-care interventions are made in
the first year, while the cumulative effects of the treat-
ment will become more and more visible after the treat-
ment is finished. Therefore it might be necessary to
perform a follow up study when the results indicate such
a delay in cumulative effects.
Another possible limitation is that it is not possible to
blind patients and caregivers to the randomisation due
to the nature of the stepped-care program. However,
considering the pragmatic design of the study, this is a
true representation of clinical practice and this also en-
ables us to measure all possible effects of the interven-
tion. We try to counter possible contamination between
treatments groups by using a cluster randomized con-
trolled design, in which staff from usual care practices
are not trained to perform the stepped-care program
until after the follow up period. That way, caregivers
cannot unintentionally apply aspects of the stepped-care
program to their usual care for patients.
Overall, this study will provide valuable information
about the cost-effectiveness and feasibility of a stepped-
care program in primary care to prevent major depression
in DM2/CHD patients with subthreshold depression, both
from a clinical and societal perspective. When the
stepped-care program proves to be cost-effective, the re-
sults of this study will offer a unique venture point for
implementation of the stepped-care program into primary
care and further research. The first results of this trial are
expected in 2015.
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